More supply for AtCor

By Dylan Bushell-Embling
Wednesday, 08 October, 2008

AtCor Medical [ASX: ACG] has signed an agreement to supply its SphygmoCor systems and clinical trial support services to an international pharmaceutical company.

The contract is worth at least US$930,000 [AUD$1.3 million], and has brought to US$3.7 million [AUD$5.2 million] the total value of pharmaceutical trial contracts secured by AtCor in the past 130 days.

SphygmoCor visibly identifies the effects of reflected blood pressure in the central aortic wave. This measure can't be detected with standard blood pressure monitoring.

Content from other channels on our network

A matter of influence: getting over the 'ick' with recycled water

How sustainability is shaping network strategy

Upcycled mattresses to become sustainable insulation

Study finds the most effective global climate policies

UV used to make recyclable, sustainable polymers

St Vincent's Hospital Sydney junior doctors class action underway

Hospital waiting times remain high, new Productivity Commission data reveals

From vision to vigilance: building a secure digital future for health care

The Emergency Department Access & Performance Conference

REDFEB highlights the impacts of chronic stress on the heart

Endress+Hauser acquires particle analysis specialist

ABB introduces DCS modernisation program

foodpro 2026 now open for registrations

The missing middle: Solving the logic solver gap in SIS design

Queensland Government opens $79m manufacturing grant program

More supply for AtCor

argenx and Monash University partner against autoimmune diseases

Archer completes potassium sensing alpha prototype

Farm animals and aquaculture cryopreservation partnership announced

Content from other channels on our network